Sierra is the licence holder for Sareum-developed SRA737. The posters will outline pre-clinical results from its research, including late breaking data. They will be on show at the American Association of Cancer Research annual meeting in Chicago.
Poster one will reveal that checkpoint kinase-1 inhibitor SRA737 is active in both PARP inhibitor-resistant and CCNE1 high-grade serous ovarian cancers.
Synergies with PARP inhibitor
Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.
PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.
Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.
Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer.
The shares rose 0.045p to 0.9p.